Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...